Company ProfilePremium

Jayex Technology Limited (formerly Jayex Healthcare Limited)

Company Profile Analysis

Ticker: JTL.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Jayex Technology Limited - Company showcase

Year Founded & Workforce

1978

Jayex Technology Limited logo

Jayex Technology Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Jayex Technology Limited Overview

ItemDetailSource
Current legal name (listed entity)Jayex Technology LimitedFY2021 Appendix 4E; ASX
Former nameJayex Healthcare Limited (until 31 May 2021)Market Index former names register
ABN15 119 122 4771H FY2022 Appendix 4D
Holding company incorporation2006, Australia (the ACN 119 122 477 series indicates a 2006 registration; MarketBeat gives "founded 2006")MarketBeat; ABN
Operating brand founded1978 (Jayex, UK LED information displays)jayex.com "About"; CB Insights
Incorporation jurisdictionAustralia (Corporations Act 2001)1H FY2022 Appendix 4D, Note 1
Registered office / principal place of business (latest disclosed)Level 4, 100 Albert Road, South Melbourne, VIC 32051H FY2022 Appendix 4D, Note 1
Earlier head office17B Cribb Street, Milton, QLDCB Insights; MarketBeat
Exchange / tickerASX: JTL (formerly JHL); suspendedMarket Index
ASX listing date17 December 2015Market Index corporate details
ISIN / CUSIPASX ISINs follow the AU0000000XXX format, but the specific code was not confirmed for this dossier. No CUSIP (no US listing).—
Fiscal year end31 DecemberAppendix 4E FY2021
Employees (latest)Not publicly disclosed. Proxy: employee benefits expense A$3.15m (FY2020) and A$3.05m (FY2021).FY2021 Appendix 4E
AuditorWilliam Buck Audit (VIC) Pty Ltd1H FY2022 review report; Market Index
Share registryAutomic GroupMarket Index
Shares on issue281.28 million (31 Dec 2022 and 31 Dec 2023)Morningstar via Market Index
Market capitalisation (current)About A$0.28m at the last trade of A$0.001; non-tradeable while suspendedSimply Wall St (A$281.3k); Market Index
Market capitalisation, 31 Dec 2023A$2.53m (EV A$6.06m)Morningstar via Market Index
Website (listed entity, historical)jayex.com/en-au/ and jayex.com.au (historical)Source list; Simply Wall St
Website (current operator)jayex.com (© 2026 Jayex Limited)jayex.com

Jayex is one of the longest-established suppliers of patient-flow technology to UK primary care. Its products cover self check-in kiosks, patient calling displays and waiting-room management. They are sold mainly to NHS GP practices, Primary Care Networks and community trusts on recurring licence-plus-hardware contracts. The listed Australian parent, Jayex Healthcare/Jayex Technology Limited, was assembled in 2015 around the UK business and an Australian appointments app (Appointuit). It later tried adjacent bets, including remote pharmacy dispensing (BluePoint) and a New Zealand medicinal cannabis licence (Whakaora Hou). None reached scale.

Revenue never exceeded about A$7.2m. The group was persistently loss-making and relied on related-party funding from its chairman's interests. It exited acute hospital queue management in 2021, and its UK operating company entered administration in August 2024. The franchise survives commercially under private owner Jayex Limited, which claims more than 1,800 UK practices on active subscriptions. For the listed company's equity holders, the investment case has effectively ended.


Company's own description (paraphrased)

In its 2020 annual report and its 2021–2022 filings, the company described its principal activities as follows (paraphrased):

  • providing service technologies to the healthcare industry; and

  • developing integrated dispensing automation systems for the pharmaceutical and healthcare sectors.

After the 2021 divestment of the acute hospital business, the 1H FY2022 report narrowed this focus. Growth would come from UK primary care and NHS community markets through the company's SaaS-based Jayex Connect platform, supported by continued product innovation.

Market Index's company profile (drawn from company materials) describes a business evolving to support how patients now want to engage with their GP. That includes social prescribing and care navigation alternatives across primary care.

Independent characterisation

Jayex is best understood as a niche, hardware-enabled vertical SaaS vendor in UK primary-care front-office workflow. Its core value proposition is threefold:

  1. Patient arrival (self check-in): A touchscreen kiosk (floor, wall or desk mounted) or mobile check-in via SMS link or QR code. It verifies the appointment against the practice's clinical system and marks the patient as arrived. It can also capture or update demographic data such as mobile number and email.

  2. Patient calling: Screens in the waiting room call patients to clinicians. They show the patient's name or a ticket number, which supports privacy and GDPR compliance, and display health messaging between calls.

  3. Waiting-room visibility and engagement: A live dashboard of waiting patients (branded QView under Jayex Limited), plus surveys, campaigns, an information hub and reporting.

The key technical moat is integration with the UK GP clinical systems: EMIS Web (now Optum), Vision (INPS, now Cegedim) and TPP SystmOne. Each integration requires accreditation and partner status. Jayex was listed as a partner in the EMIS and Vision partner directories, and NHS Digital certified its Enlighten E4 product with TPP SystmOne appointments. Health Tech Newspaper (htn.co.uk) reported that Jayex was at that time the only provider integrated with all three systems for both patient calling and self-arrivals.

Revenue model

Revenue stream (AUD)1H20211H2022
Supply and installation of kiosks (point in time)769,7061,152,038
Software licences and support services (over time)923,5091,119,133
Extended warranty (over time)132,819248,625
Software development support services (over time)4,7300
Total revenue from continuing operations1,830,7642,519,796

The group's revenue in the last period disclosed by product line (1H FY2022) split into four streams:

Source: 1H FY2022 Appendix 4D, Note 5: Recurring streams (licences and support, extended warranty) were about 54% of 1H FY2022 revenue (derived). Hardware supply and installation made up about 46% (derived). This mix shows a hybrid model: kiosk and screen hardware is sold or installed up front, and multi-year software licences and support produce annuity revenue.

Contract liabilities (deferred revenue) were A$1.44m at 30 June 2022, which confirms that customers are invoiced in advance for licences and warranties. Q3 FY2022 commentary reported 883 annual licences billed, up from 776 in Q3 2021 (Stockhead quarterly round-up).

Value chain position

Jayex designs the software and integration layer and sources commercial-grade touchscreens and displays (anti-microbial coated screens are mentioned in partner materials). It also installs, maintains and supports the systems. Jayex Limited emphasises on-site engineer swap-out for failed hardware. It also runs its clinical-system integration on a dedicated Jayex-supplied PC inside the practice network, so that clinical data does not leave the practice.

Jayex sits downstream of the clinical-system vendors (EMIS, TPP, Cegedim/Vision), on whom it depends for API access and accreditation. It sits upstream of practices, PCNs, federations and NHS trusts, which buy directly or through NHS frameworks.

Customer types and end-markets

End-marketCustomer typesStatus
UK primary careGP practices, PCNs, GP federations, practice groups (e.g., Operose Health, Howbeck Healthcare, Sunderland GP Alliance named on jayex.com)Core; continued under Jayex Limited
UK community and acuteNHS community trusts (e.g., Hertfordshire Community NHS Trust), hospital outpatient departmentsCommunity continued; on-premises acute queue management sold to VitalHub in May 2021
Australia and New Zealand primary careGP clinics (integration with MedicalDirector Pracsoft), Appointuit app usersScaled back in 2022; sales and product roles moved to the UK
Australian acuteLocal Health Districts (e.g., North Sydney LHD QMS with Cerner)Sold to VitalHub in 2021
Pharmacy / dispensingBluePoint remote dispensing terminals; 2018 licence to Medicann NZDormant / not material
Medicinal cannabis (NZ)Whakaora Hou Limited cultivation licenceSale to Bioarc fell through in 2022; not commercialised

Strategy

Stated strategy themes (latest filings accessed, paraphrased)

From the 1H FY2022 Directors' Report:

  1. Focus: UK primary care and NHS community markets through the SaaS Connect platform, after exiting acute.

  2. Innovation-led growth: Rollout of new products, including the Connect Information Kiosk and a Survey module.

  3. Cost restructuring: Streamlined ANZ operations, with roles moved to the UK.

  4. Balance sheet support: Ongoing related-party funding, with the Covenant note extended to 13 October 2023 and expected to be settled in equity.

  5. Opportunistic adjacencies: Remote patient monitoring ("home care") was flagged in FY2020. Partnership-led expansion in New Zealand was mentioned in the FY2020 report (counterparty not identified in the excerpt accessed).

Market Index's company profile adds social prescribing and care navigation alternatives across primary care as strategic directions.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

The listed entity has made no strategic announcements since its June 2024 quarterly report (lodged 5 August 2024). Under Jayex Limited, the operating business has:

  • renewed ISO/IEC 27001:2022 certification (issued 16 January 2026) and certified to Cyber Essentials Plus (18 December 2025);

  • launched or rebranded QView waiting-room management and repositioned the website around GP practices, PCNs and hospitals;

  • published customer metrics: 1,800+ UK practices on active subscriptions, 98%+ annual retention (derived from monthly recurring revenue churn, 2025–26), a 4.7/5 support rating and 62% likelihood-to-recommend scores of 4–5 out of 5 (May 2026 survey, n=183).

ESG and cost programmes

No formal ESG commitments, emissions targets or quantified cost programmes were disclosed by the listed entity.

Medium-term targets and guidance

None were disclosed. The 1H FY2022 impairment testing used a one-year management forecast of year-on-year revenue growth from FY2023 onwards. Actual FY2023 revenue declined about 19%.

Products & Services

Primary care — Patient engagement (UK segment; now Jayex Limited)

ProductDescription and capabilitiesTarget customerLaunch / latestPricing
Jayex Connect platformCloud-based patient engagement platform combining check-in, calling, messaging, surveys and reporting. Needs no Microsoft updates on practice machines. Offers enterprise licensing and central reporting for PCNs and federations.GP practices, PCNs, federationsPlatform converged 2018; continuously updatedAnnual licence plus hardware; enterprise licensing for groups. Specific prices not publicly disclosed.
Patient Check-in (kiosk)Commercial-grade touchscreen kiosk (floor, wall or desk), height and wheelchair accessible, anti-microbial coating. Content in 45–48+ languages. Integrated arrival into EMIS, Vision or SystmOne. Up to 11 demographic fields can be reviewed or captured.GP practices, community clinicsFirst kiosk developed 2004; current versions are Connect modulesHardware supply and installation plus licence
Patient Mobile Check-inCheck-in through an SMS link or a practice-specific QR code.GP practicesConnect-era moduleAdd-on
Patient CallingWaiting-room displays calling patients by name or number, with health messaging. Descended from the D300 display.GP practices, clinics, hospitalsD300 from 1996; Connect calling currentHardware plus licence
QView waiting-room managementLive list of waiting patients by name or number, showing wait times and clinician, with "running late" flags.Reception teamsBranded under Jayex Limited (2025–26 website)—
Waiting-room media and screensDigital signage with practice and health content.GP practicesCurrent—
Patient Communications / SurveysSurvey creation, SMS or email patient contact, check-in and check-out surveys, campaigns. A "Survey" innovation was cited as ready for rollout in 1H FY2022.GP practices, PCNs2,022Add-on
Patient Information HubHealth and practice information delivered at check-in, aimed at reducing digital health inequalities.GP practicesConnect-eraAdd-on
Connect Information KioskClinic kiosk for rebooking appointments, completing surveys and searching clinic online resources.GP practicesDevelopment completed 1H FY2022—
Enlighten (E4)Earlier web-based waiting-room management for multi-practice sites, acute trusts, LIFT buildings and polyclinics. NHS Digital certified pairing with TPP SystmOne appointments. Trial data: 548 check-ins flagged 62 missing or incorrect mobile numbers and 78 emails.Multi-practice sites, health centresPre-Connect generationLegacy
X-TouchSelf check-in software pre-installed on touchscreens, communicating with InPS Vision 3.0. Developed with InPS.Vision practicesLaunched March 2005Legacy
D300 Patient Calling DisplayClassic patient-calling LED or LCD display.GP practices1,996Legacy

Acute / hospital (divested May 2021)

ProductDescriptionCustomerStatus
QMS (Queue Management System)On-premises hospital queue management with HL7 integration, deployed with Cerner at North Sydney LHD.NHS trusts; Australian LHDsHospital contracts in the UK and Australia sold to VitalHub (TSXV: VHI) on 17 May 2021

Australia / New Zealand

ProductDescriptionCustomerStatus
AppointuitOnline appointment booking and patient engagement app, launched in 2011 and once Australia's most popular medical appointment app on the App Store and Google Play (Pulse+IT, 2015).Australian GP clinics and patientsFounders exited in 2017; later status not disclosed
Jayex kiosks for PracsoftSelf check-in integrated with MedicalDirector Pracsoft (from version 3.15.3a). Marks patients as "Waiting" in the Pracsoft waiting room.Australian GP clinicsAustralian operations scaled back in 2022

Pharmacy and dispensing automation

ProductDescriptionCustomerStatus
BluePointRemote pharmacy prescription processing and dispensing terminal, with kiosks. Licensed to Medicann NZ in July 2018 for a minimum of A$500k.Pharmacies; cannabis dispensariesNo later commercial disclosures; dormant
Pharmacy DeliveryListed by Market Index as one of four proprietary technologies (with Enlighten, Appointuit and BluePoint).Pharmacies—

Other ventures

AssetDescriptionStatus
Whakaora Hou LimitedNZ subsidiary holding a cannabis cultivation licence.Bioarc withdrew its purchase offer in 1H 2022, citing poor NZ cannabis market conditions
Remote patient monitoring / home careExplored as a growth segment in the FY2020 annual report.No product disclosed

Financial Narrative

Sources by year:

  • FY2019: FY2020 Annual Report comparatives.

  • FY2020 and FY2021: FY2021 Appendix 4E (FY2020 restated for discontinued operations).

  • FY2022 and FY2023: Morningstar data via Market Index. Audited full-year statements for these years were not directly accessed, so they are aggregator figures.

All figures are in A$ thousands unless stated.

Income statement

Notes:

  • FY2020 EBITDA (derived) includes a A$246k derivative fair-value gain and a A$106k foreign exchange gain.

  • FY2021 EBITDA (derived) includes the A$2,514k impairment and a A$1,038k derivative fair-value gain.

  • FY2023 D&A is reported as nil by Morningstar, consistent with intangibles having been fully written down by 31 December 2022.

  • Simply Wall St reports FY2023 revenue as A$3.8m (likely including other income), cost of revenue A$4.1m and gross profit of –A$330k. This is a different classification from the "revenue less raw materials" proxy above.

Margins and growth

FY2020 growth is measured against FY2019 on the originally reported basis (6,063 vs 7,185). The FY2021 growth rate uses the restated FY2020 continuing revenue. Morningstar's "NPAT margin" (–53.1% FY2022, –69.8% FY2023) is calculated on NPAT before abnormals.

Revenue CAGR (derived):

  • FY2020–FY2023 on the restated continuing basis (5,069 → 3,480): –11.8% a year.

  • FY2019–FY2023 on a mixed basis (7,185 → 3,480): –16.6% a year. This is not like-for-like because FY2019 includes the later-divested acute business.

Balance sheet

Notes:

  • FY2021 figures are as originally reported. After restatement, total assets were A$9,691k, intangibles A$5,177k and equity A$1,178k.

  • FY2022 and FY2023 net debt is calculated on short-term debt only (long-term debt was not available).

  • Equity was a deficiency at 31 December 2022 and 2023. Morningstar book value per share of about –A$0.02 implies roughly –A$5.6m (–0.02 × 281.28m shares, indicative only). Total assets of A$0.50m against current liabilities of A$6.53m at 31 December 2023 confirms a deficiency of at least A$6.0m.

  • The group had already reported a net liability position of –A$90k at 30 June 2022.

Cash flow

Half-year cash flow (1H FY2022): operating cash flow –A$204k; capex A$23k; repayment of borrowings A$176k; closing cash A$448k (1H FY2022 4D).

Ratios

Notes:

  • ROE and ROA for FY2020–21 are derived using average equity and assets where available.

  • FY2022–23 ROA, current ratio, quick ratio, asset turnover and inventory turnover are from Morningstar.

  • ROE is not meaningful for FY2022–23 because equity was negative. Morningstar shows positive ROE of about 36% for those years, which is an artefact of dividing a loss by negative equity.

  • Net debt/EBITDA is not meaningful because EBITDA was negative in most years.

  • ROIC and the cash conversion cycle could not be computed reliably from the disclosures accessed.

Commentary on trends, inflections and drivers

Revenue. The group peaked at A$7.2m in FY2019 (including acute). After that, three forces worked against it:

  1. COVID-19 kept patients away from GP waiting rooms through 2020–21, which collapsed demand for check-in kiosks. Remote triage and telephone consultations replaced face-to-face arrival.

  2. The May 2021 divestment of the acute QMS business removed about A$0.4m of revenue a half-year.

  3. Australian and New Zealand revenue was deliberately scaled back from 2022.

FY2022 recovered 19.9% to A$4.3m as UK practices reopened and an "in-fill" order for kiosks arrived. The recovery stalled in FY2023 (–19.1% to A$3.48m). Management attributed the slowdown to NHS technology spending being paused while Clinical Commissioning Groups were reorganised into Integrated Care Boards (ICBs went live on 1 July 2022).

Profitability. The business was loss-making at the net level in every year examined. The gross-margin proxy is high (78–84%), but operating costs were about A$5–6m against revenue of A$3.5–5m, because the cost base was built for a larger company. Losses also carried heavy non-cash charges:

FY2021: goodwill and intangible impairment of A$2.5m.

FY2022: abnormals of A$3.75m, consistent with writing off the remaining A$3.45m of UK goodwill and other intangibles. Intangibles fell to nil by 31 December 2022.

FY2023: abnormals of A$1.5m, consistent with writing off the A$1.4m Brainworks investment. Non-current investments fell to nil.

Underlying EBITDA swung from roughly breakeven in FY2020 to –A$2.4m in FY2023, a clear deterioration in the core business.

Balance sheet. Total assets shrank from A$12.4m to A$0.5m in four years as goodwill, intangibles and investments were written off. The group was funded by:

  • related-party convertible notes and loans (Covenant Holdings (WA), linked to chairman Michael Boyd);

  • two £600k NatWest loans at 2.05% (repayable by June 2026 and February 2027);

  • small equity raisings (A$0.7m in FY2020; A$1.3m in FY2021, including the September 2021 rights issue at A$0.025).

The auditor flagged a material uncertainty about going concern in the 1H FY2022 review report. By 31 December 2023 the current ratio had fallen to 0.08x and cash to A$50k. The UK administration in August 2024 followed from this.

Cash flow. Operating cash burn widened from –A$0.18m (FY2020) to –A$1.26m (FY2021). Capex was minimal (A$0.1–0.3m), so R&D was evidently not capitalised at scale. Free cash flow was negative in every year accessible.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment (AUD) and Revenue by Segment (%)

Segment metric (AUD)1H20211H2022

Australia revenue

325,464190,864

United Kingdom revenue

1,505,3002,328,932

Total revenue

1,830,7642,519,796

Australia EBITDA

-444,487-433,687

United Kingdom EBITDA

513,33132,347

Group segment EBITDA

68,844-401,340

Australia share of revenue (%)

17.87.6

United Kingdom share of revenue (%)

82.292.4

Segment Assets & Liabilities (AUD)

Segment balance sheet (AUD)Dec2021Jun2022

Australia total assets

2,909,9542,622,839

United Kingdom total assets

6,781,5455,796,466

Australia total liabilities

3,538,0983,868,758

United Kingdom total liabilities

4,975,7784,640,665

Group Entities

EntityJurisdictionRoleStatus

Jayex Technology Limited (formerly Jayex Healthcare Limited)

Australia

ASX-listed parent

Suspended

Jayex Technology Limited (UK)

England & Wales

Main operating company (UK CGU)

Administration from Aug 2024; business sold

Australian operating entity / Appointuit

Australia

AU primary care; app

Scaled back 2022

Whakaora Hou Limited

New Zealand

Holder of NZ cannabis cultivation licence

Held; sale to Bioarc withdrawn 2022

Jayex Limited (not a group entity)

UK

Current owner of the Jayex business

Private; acquired the business in 2024

Income Statement and Per-Share Data

Metric (AUD K)FY2019FY2020FY2021FY2022FY2023

Revenue, as originally reported

7,1856,0633,5864,3003,480

Revenue, continuing operations (restated basis)

—5,0693,5864,3003,480

Other income

—545251190330

Raw materials and consumables

—1,091571——

Revenue less raw materials (derived gross profit proxy)

—3,9783,015——

Employee benefits expense

—3,1513,048——

Depreciation and amortisation

—8546066300

Impairment of intangibles / abnormals

—02,5143,7501,500

EBITDA (derived FY2020–21; Morningstar FY2022–23)

—136-2,753-820-2,420

Underlying EBITDA excl. impairment and derivative fair-value gains (derived)

—-110-1,277-820-2,420

EBIT / operating income (derived FY2020–21; Morningstar FY2022–23)

—-718-3,359-1,450-2,420

Finance costs

—380841930170

Pre-tax income, continuing (FY2022–23 pre-abnormals)

—-1,098-4,200-2,370-2,590

Net income attributable to owners

-960-799-3,724-7,250-3,930

EPS basic (A$ cents)

—-0.4-1.7-2.9-1.45

EPS diluted (A$ cents)

—-0.4-1.7-2.9-1.45

Dividends per share (A$ cents)

00000

Margin Analysis (%)

Metric (%)FY2019FY2020FY2021FY2022FY2023

Revenue growth YoY (restated basis)

—-15.6-29.319.9-19.1

Gross margin proxy (revenue less raw materials)

—78.584.1——

EBITDA margin

—2.7-76.8-19.1-69.5

Underlying EBITDA margin

—-2.2-35.6-19.1-69.5

Operating (EBIT) margin

—-14.2-93.7-33.7-69.5

Net margin (reported NPAT / revenue)

-13.4-15.8-103.8-168.6-112.9

Balance Sheet

Metric (AUD K, at 31 December)FY2019FY2020FY2021FY2022FY2023

Total assets

—12,35910,0772,310500

Cash and equivalents

2811,18298324050

Short-term borrowings

—2,9612,6076,1502,760

Long-term borrowings

—1,7162,455——

Total borrowings

—4,6775,062——

Net debt (derived)

—3,4954,0795,9102,710

Total equity

4,1613,3771,483——

Goodwill and intangibles

—9,2375,54500

Total current assets

—2,7522,117810500

Total current liabilities

—6,7615,87010,7506,530

Working capital (derived)

—-4,009-3,753-9,940-6,030

Contract liabilities (deferred revenue)

—1,4361,615——

Issued capital

26,16626,86128,112——

Accumulated losses

-20,557-21,356-25,080——

Cash Flow

Metric (AUD K)FY2019FY2020FY2021FY2022FY2023

Operating cash flow

—-183-1,257——

Capex (PP&E plus intangibles)

—271135——

Free cash flow (derived)

—-454-1,392——

Proceeds from share issues (gross)

—7001,292——

Proceeds from borrowings

—1,0601,116——

Proceeds from disposal of acute business

—01,584——

Payment for investments (Brainworks)

—01,369——

Dividends paid

00000

Share buybacks

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2020FY2021FY2022FY2023

ROE (%)

-21.2-153.3——

ROA (%)

—-33.2-71.0-458.9

Current ratio (x)

0.410.360.070.08

Quick ratio (x)

——0.060.05

Debt / equity (x)

1.383.41——

Interest coverage, EBIT / finance costs (x)

-1.9-4.0-1.6-14.2

Asset turnover (x)

0.410.321.866.91

Inventory turnover (x)

——30.8920.65

Region revenue (AUD)

Region revenue (AUD)1H20211H2022

United Kingdom

1,505,3002,328,932

Australia (including NZ)

325,464190,864

Total

1,830,7642,519,796

Region growth and share (%)

Region growth and share (%)1H20211H2022

United Kingdom growth YoY

—54.7

Australia growth YoY

—-41.4

United Kingdom share of total

82.292.4

Australia share of total

17.87.6

UK CGU revenue (GBP)

UK CGU revenue (GBP)FY2021

UK CGU revenue used for impairment testing

2,512,537

Per-Share Data and Share Count (millions)

Metric (A$ per share)FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024

June share price close

0.1450.0230.0250.0480.0180.0260.0050.0090.001

Metric (AUD Mn, 31 December)

FY2022

FY2023

———————

Market capitalisation

3.092.53———————

Enterprise value

10.966.06———————

Shares outstanding (millions)

281.28281.28———————

Share Price & Returns

PeriodReturn (%)

1-year (Jun 2023 to Jul 2024)

-88.9

3-year (Jun 2021 to Jul 2024)

-96.2

5-year (Jun 2019 to Jul 2024)

-97.9

Since listing year (Jun 2016 to Jul 2024)

-99.3

Valuation Multiples

Multiple (x)FY2022FY2023

P/E

-1.20-1.00

Price / book

-0.49-0.37

Price / cash flow

-8.03-1.50

EV / sales (derived: EV ÷ trading revenue)

2.551.74

Capital Instruments

InstrumentFace / carryingRateMaturityOutcome

Covenant convertible notes

Face A$2.7m (carrying A$2.52m)

6.5%

13 Oct 2022, extended to 13 Oct 2023

Converted Mar 2023 (250m securities at A$0.015)

Related-party loan (Covenant)

A$0.74m

0% (unsecured)

1 Apr 2023

—

NatWest loan 1

£600k original (£480k outstanding)

2.05%

Jun 2026

Obligation of the UK subsidiary; subject to the administration

NatWest loan 2

£600k original (£560k outstanding)

2.05%

Feb 2027

Same as above

Lease liabilities

A$0.18m

—

Short-dated

—

“—” = not publicly disclosed.

Analyst Conclusions

Management guidance

None. The listed entity has issued no guidance since its last periodic report (5 August 2024). Its last forward-looking statement (1H FY2022) expected improved UK trading and year-on-year revenue growth from FY2023. That did not happen: FY2023 revenue fell about 19%.

Consensus

No coverage exists, so there is no consensus.

Bull-case arguments (franchise-level; limited relevance to JTL equity)

  1. The franchise survived insolvency intact. Jayex Limited kept the products, engineers and support team. It reports 1,800+ practices and 98%+ annual retention, showing the customer base is worth more than the listed group's capital structure implied.

  2. Integration moats endure. Accredited integration with EMIS, Vision and SystmOne, plus dedicated in-practice hardware, creates high switching costs. The listed group's 84% gross-margin proxy (FY2021) suggests attractive unit economics once overhead is right-sized.

  3. Recapitalised ownership can invest. Freed from A$5–6m of debt-like liabilities and listed-company costs, a private owner could pursue PCN enterprise licensing, survey modules and hardware refresh cycles that the listed group could not fund.

Bear-case arguments

  1. JTL equity is likely worthless. The listed parent lost its main operating subsidiary to administration. It reported cash of A$50k and an equity deficiency of at least A$6m at 31 December 2023, and is likely to be removed from the ASX.

  2. Structural demand erosion. Digital-first GP access and remote triage reduce waiting-room dependence, and revenue fell at an –11.8% CAGR from FY2020 to FY2023 on a like-for-like basis.

  3. Platform-owner and scale risk. Clinical-system vendors and well-funded communications platforms (Accurx, iPlato) can bundle arrival and calling features. A sub-A$5m vendor has little R&D capacity to respond.

Catalysts and monitorables (next 12 months)

  1. ASX confirmation of removal of JTL from the official list (expected around August 2026; verify).

  2. FRP Advisory administrators' progress reports (Companies House): sale consideration and returns to creditors, including any intercompany claim by the Australian parent.

  3. Any liquidation or deregistration of the Australian parent and its NZ subsidiary (Whakaora Hou).

  4. Jayex Limited customer metrics, accreditation renewals (ISO 27001 expires 25 January 2027; Cyber Essentials Plus expires 18 December 2026) and any NHS framework awards.

  5. NHS policy on GP digital front-door funding, and native features from EMIS/Optum and TPP.

Concluding analyst verdict

Jayex Healthcare Limited, renamed Jayex Technology Limited in May 2021, is a cautionary case of a sound niche franchise held inside an unsustainable listed structure. The underlying asset was a 1978-vintage UK patient-flow business. It had integrations with every major GP clinical system, an installed base in the low thousands of practices and a high gross margin. The 2015 listing bundled that asset with Australian adjacencies that never earned their keep, including Appointuit, BluePoint, a New Zealand cannabis licence and a later US$1m bet on Brainworks.

Revenue peaked at about A$7.2m in FY2019. COVID-19 then emptied GP waiting rooms, the acute business was sold to VitalHub in 2021, and NHS spending paused during the 2022 ICB reorganisation. By FY2023, revenue of A$3.48m supported a cost base that produced an EBITDA loss of about A$2.4m. Cumulative net losses from FY2019 to FY2023 were about A$16.7m, and goodwill and investments of more than A$10m were written off.

Throughout, the group survived on related-party funding from its chairman's interests. That created heavy governance concentration and left minority holders highly diluted. The end came in 2024: repeated ASX suspensions, then the UK operating company's administration in August. The business was sold to private buyer Jayex Limited.

For holders of JTL shares, our assessment is that recoverable value is negligible to nil, and the security should be treated as a write-off pending formal ASX removal. Any residual value would depend on administrators' distributions or intercompany claims, which appear unlikely. For strategic observers, the Jayex franchise looks healthy under private ownership: 1,800+ practices, 98%+ retention and renewed ISO 27001 and Cyber Essentials Plus accreditation. It remains a credible acquisition target or partner for a larger UK primary-care software group.

Verdict: JTL equity is uninvestable. The Jayex franchise (Jayex Limited) is a niche asset worth monitoring as private-market or M&A intelligence.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure / datesBackground (as disclosed)Holdings (latest notice)

Michael Denis Boyd (B.Com)

Chairman (Executive Chairman in 2022 filings; recorded as Non-Executive Chairman from Oct 2022)

Director since listing (2015); moved to a non-executive role in Jun 2017; signed the 2022 reports as Chairman

Over 27 years founding enterprises in healthcare, telecoms and finance. Founded Foundation Healthcare, which grew to more than 800 healthcare professionals before being acquired by Sonic Healthcare; described by Pulse+IT as a Sonic Healthcare co-founder. Founding partner of Iridium Satellite during its emergence from bankruptcy.

Indirect 110,883,880 shares; 250,000,000 options/convertibles (notice 2 May 2024)

Brian Renwick

Non-Executive Director

Director through the 2021–2024 filings; consultant to Jayex since 2006

Pharmaceutical manufacturing and supply-chain roles, then wholesale business development in retail and hospital pharmacy. General manager of a corporate pharmacy business; two business development roles within the CSL Limited group.

1,660,871 shares (notice 2 May 2024)

Michael Chan

Non-Executive Director

——

Previously 624,545 shares from the 2021 rights issue plus on-market purchases

Nicholas Harper

Executive Director

—

Senior UK operational role implied (Executive Director); details not disclosed

—

William Denis Boyd

Non-Executive Director

Appointed June 2024

—

0 shares (notice 4 Jun 2024)

“—” = not publicly disclosed.

Governance Detail

RoleNameNotes

CEO / Managing Director

Not publicly disclosed in documents accessed

The Executive Chairman (Michael Boyd) and Executive Director (Nicholas Harper) appear to have performed executive functions in 2022

CFO / Company Secretary

Not publicly disclosed in documents accessed

—

Jayex Limited (current operator) leadership

Not publicly disclosed on jayex.com

—

Board & Management Changes

DateChange

Jun 2017

Michael Boyd moves to a non-executive role (Pulse+IT)

2022

Board comprises Boyd (Executive Chairman), Renwick, Chan and Harper

Oct 2022

Boyd recorded as Non-Executive Chairman (Market Index)

Jun 2024

William Denis Boyd appointed Non-Executive Director

Major Shareholders

RankHolderShares%
1

Lirho Pty Ltd <Boyd 4 A/C>

103,883,88036.93
2

Vector London Ltd

19,003,3786.76
3

Mary Kathleen Simcox

17,500,0006.22
4

Donovan Products Pty Ltd <Family A/C>

12,035,9434.28
5

Turbine Capital Limited

8,800,0003.13
6

Covenant Holding (WA) Pty Ltd

7,000,0002.49
7

Citicorp Nominees Pty Limited

6,455,1632.29
8

BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient>

5,990,3272.13
9

Mr Joel David Webb

5,500,0001.96
10

Mrs Vanessa Faye Connor

5,174,8081.84

Competitive Landscape

Key Competitors

CompetitorHQSegment overlapRelative positioning vs Jayex

Qmatic

Sweden

Queue management and customer flow, including healthcare

Global scale; strong in hospitals and public sector; less GP-system integration depth

Wavetec

UAE / UK

Queue management kiosks and displays

Generalist queue management; competes on hardware

Q-nomy

Israel

Queue and appointment management for healthcare and government

Enterprise focus

VitalHub Corp (TSXV: VHI)

Canada

Patient flow and queue management in the UK acute market (owns Jayex's former acute QMS contracts)

Larger, acquisitive; now the acute incumbent where Jayex exited

Accurx

UK

GP patient messaging, online consultation, booking

Dominant in UK GP digital communications; adjacent rather than kiosk-based

iPlato (myGP)

UK

Patient messaging, app, booking

Adjacent; patient engagement via mobile

EMIS / Optum Patient Access

UK

Patient app, online booking, arrivals features in the clinical system

Platform owner and partner; risk of native features displacing third parties

TPP (SystmOne / Airmid)

UK

Clinical system with patient-facing features

Same platform-owner risk

Envisage-type UK check-in kiosk vendors and local AV/IT integrators

UK

GP self check-in and calling screens

—

HotDoc

Australia

GP booking, check-in, recalls

Dominant in Australian primary care booking; displaced Appointuit-type apps

HealthEngine

Australia

Consumer appointment booking

Same as above

Omnicell / BD Rowa

US / Germany

Pharmacy dispensing automation

Far larger; makes BluePoint uncompetitive

Competitor Detail

MetricJayex (FY2023)

Revenue (AUD Mn)

3.48

Revenue growth (%)

-19.1

EBITDA margin (%)

-69.5

Net margin (%)

-112.9

R&D intensity (capitalised development % revenue, FY2021)

2.5

Listed

ASX (suspended)

Recent Developments

The listed entity has published no identifiable announcements since August 2024, so the 18-month window holds few listed-company events.

Company Snapshot

1978

Founded

South Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Full UK GP-system coverage: Health Tech Newspaper reported that Jayex was the only provider integrated with EMIS, Vision and TPP SystmOne for both calling and arrivals, on all platforms.
  • Recurring revenue base: Licences, support and warranty were about 54% of 1H FY2022 revenue (A$1.37m of A$2.52m).
  • High gross-margin proxy: Revenue less raw materials was 78.5% (FY2020) and 84.1% (FY2021).
  • Sticky installed base: 2,327 customers on the platform (1H FY2022). Jayex Limited reports 1,800+ UK practices and 98%+ annual retention (2025–26).
  • Long-standing security accreditation: ISO 27001 certified continuously since 26 January 2015.
  • No customer concentration: No customer was 10% or more of revenue (1H FY2022 Note 4).
  • Advance billing: Contract liabilities of A$1.6m at 31 December 2021 show customers invoiced ahead of delivery.

Weaknesses

  • Persistent losses: Net losses every year from FY2019 to FY2023, totalling about A$16.7m (derived: 0.96 + 0.80 + 3.72 + 7.25 + 3.93).
  • Insolvent balance sheet: Current ratio of 0.08x and cash of A$50k at 31 December 2023; equity deficiency.
  • Repeated impairments: A$4m (FY2016); A$2.5m (FY2021); A$3.75m of abnormals (FY2022); A$1.5m (FY2023).
  • Dependence on related-party funding: A$3m Covenant convertible notes plus a A$0.74m related-party loan.
  • Governance concentration: The chairman's interests held about 39% of shares plus 250m options/convertibles; the board was small with limited independence.
  • Shrinking revenue: Restated revenue CAGR of –11.8% a year, FY2020–FY2023.
  • Going-concern uncertainty: Material uncertainty flagged in the 1H FY2022 auditor review.

Opportunities

  • PCN and federation enterprise licensing: About 1,250 PCNs (approximate) suit centralised deals; Jayex markets enterprise tools.
  • Data capture for digital inclusion: Demographic correction at check-in was demonstrated in the Enlighten E4 trial.
  • Hardware refresh cycles: A large installed base of ageing kiosks and screens.
  • Community and outpatient expansion: Hertfordshire Community NHS Trust is a reference customer.
  • Survey and campaign modules: These add software-only revenue per site; the Survey module was ready in 2022.
  • Recapitalisation: New investment under Jayex Limited (2024) removes the listed group's funding constraint.

Threats

  • Platform-owner encroachment: EMIS/Optum and TPP control integration and could offer native arrival features.
  • Digital-first access policy: Remote and online access reduces footfall-dependent products; the COVID collapse of FY2020–21 is the clearest example.
  • NHS spending pauses: The ICB transition slowed UK trading in Q3 FY2022.
  • Well-funded digital competitors: Accurx and iPlato in patient communications; VitalHub in acute.
  • ASX delisting: Effectively worthless equity for remaining JTL shareholders after the UK administration.
  • Cyber and data-protection regulation: UK GDPR and NHS DSPT obligations raise compliance costs for small suppliers.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
31 Jan 2024December 2023 Quarterly Update and Appendix 4CLast full-year quarterly before the suspensions
29 Feb 2024FY2023 Appendix 4E: revenue about A$3.48m, NPAT –A$3.93m, cash A$50kSevere liquidity stress disclosed
28 Mar 2024Voluntary suspensionPrecedes the annual report deadline (31 March for December year-ends)
2 Apr 2024Suspension from quotationConsistent with non-lodgement of the audited annual report by the ASX deadline (inferred; reason not confirmed)
2 May 2024Director interest and substantial holder notices (Boyd interests 39.42%; Renwick)Ownership update
9 May 2024Trading haltImplies trading had resumed briefly; reason not confirmed
4 Jun 2024William Denis Boyd appointed NED (initial interest notice)Board change
1 Aug 2024Suspension from quotationStart of the continuous suspension; last trade A$0.001 on 31 Jul 2024
5 Aug 2024June 2024 Quarterly Activity Report and Appendix 4CLast periodic disclosure identified
Aug 2024UK subsidiary Jayex Technology Limited enters administration; FRP Advisory (Kinninmonth, Prior) appointed. UK accounts to Dec 2022 showed about £3.5m current assets and just over £1m net assets.Loss of the main operating asset for the listed group
27 Aug 2024Administration posted in the London GazettePublic confirmation
2024 (H2)Jayex Limited acquires the Jayex businessBusiness continuity; value transferred outside the listed group
24 Oct 2025MarketBeat still shows a stale JHL pageAggregator data unreliable
18 Dec 2025Jayex Limited certified to Cyber Essentials Plus (whole organisation)NHS supplier assurance
16 Jan 2026Jayex Limited ISO/IEC 27001:2022 certificate reissued (valid to 25 Jan 2027)Continued security accreditation
22 Jan 2026ASX quarterly long-term suspended entities list published–
17 Apr 2026ASX long-term suspended entities list (35 entities)Same as above
May 2026Jayex Limited customer survey (n=183): 4.7/5 support ratingOperating KPI under new owner
~Aug 2026Two-year ASX suspension deadline for JTL (inferred from 1 Aug 2024 suspension)Removal from the official list likely; not confirmed
2025–26Jayex Limited publishes 1,800+ practices and 98%+ annual retentionIndicates the franchise remains viable

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue, as originally reported fell from AUD 7.2 Mn in FY2019 to AUD 3.5 Mn in FY2023.
Jayex Technology Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2019FY2020FY2021FY2022FY2023
Revenue, as originally reported7.26.13.64.33.5
Revenue, continuing operations (restated basis)—5.13.64.33.5
Revenue less raw materials ( gross profit proxy)—43——

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Market Index — JAYEX Technology Ltd (JTL) overview, financials (Morningstar), director transactions, shareholders, announcements · marketindex.com.au
  2. Market Index — announcement listings: Suspension from Quotation (2 Apr 2024; 1 Aug 2024), Voluntary Suspension (28 Mar 2024), Trading Halt (9 May 2024), Appendix 4E (29 Feb 2024), December 2023 Quarterly (31 Jan 2024), June 2024 Quarterly and Appendix 4C (5 Aug 2024)
  3. Market Index — Michael Boyd director profile (marketindex.com.au)
  4. Jayex Technology Limited — Appendix 4E, FY ended 31 Dec 2021 (asx.com.au)
  5. Jayex Technology Limited — Appendix 4D and Half-Year Financial Report, 30 Jun 2022 (asx.com.au)
  6. Jayex Healthcare Limited — Annual Report FY2020 (12 Mar 2021) (aspecthuntley.com.au)
  7. Jayex Limited — website and About page (history, accreditations, KPIs) · jayex.com
  8. CB Insights / Business Sale Report — UK administrations (Jayex Technology Limited, FRP Advisory, Aug 2024) (cbinsights.com)
  9. Stockhead — small-cap wrap, July 2018 (Medicann NZ BluePoint licence) (stockhead.com.au)
  10. Stockhead — ASX quarterlies round-up (Q3 FY2022 licences; NHS ICB slowdown) (stockhead.com.au)
  11. Pulse+IT — Appointuit acquisition (23 Sep 2015); Jayex Healthcare tag page; FY2017 results (28 Feb 2018) · pulseit.news · pulseit.news
  12. Digital Health News — InPS launches X-Touch with Jayex (29 Mar 2005) (digitalhealth.net)
  13. Health Tech Newspaper — Enlighten E4 and TPP SystmOne certification (htn.co.uk)
  14. EMIS Health partner page — Jayex Connect (emishealth.com)
  15. Vision / InPS — Jayex Connect Patient Check-in · info.visionhealth.co.uk
  16. MedicalDirector — Jayex kiosks for Pracsoft (medicaldirector.com)
  17. Building Better Healthcare — North Yorkshire GP case study (Enlighten) (buildingbetterhealthcare.com)
  18. MarketBeat — Jayex Healthcare (JHL) profile (marketbeat.com)
  19. Simply Wall St — Jayex Technology (JTL) (simplywall.st)
  20. The Motley Fool Australia — Jayex Technology (JTL) directors (fool.com.au)
  21. ASX Guidance Note 33 (removal of entities from the official list) (asx.com.au)
  22. Investor PA — ASX long-term suspended entities announcements (Jan and Apr 2026) · investorpa.com

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.